The potential role of glucagon-like peptide-1 or its analogues in enhancing glycaemic control in critically ill adult patients

Diabetes, Obesity and Metabolism

Volumn 13, Issue 2, 2011, Pages 118-129

  Combes, J ^a   Borot, S ^a   Mougel, F ^a   Penfornis, A ^a  

^a UNIVERSITÉ DE FRANCHE COMTÉ   (France)

Author keywords

Acute hyperglycaemia; Exenatide; GLP 1 analogues; Glycaemic control; Insulin intensive management; Intravenous insulin therapy; Type 2 diabetes mellitus

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; INSULIN; METFORMIN; PIOGLITAZONE; SULFONYLUREA;

CONTINUOUS INFUSION; CRITICALLY ILL PATIENT; DRUG MEGADOSE; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN TREATMENT; INTENSIVE CARE UNIT; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRITIONAL SUPPORT; PARENTERAL NUTRITION; PHARMACODYNAMICS; REVIEW; SEPSIS; SIDE EFFECT; STOMACH EMPTYING;

EID: 78650643032     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2010.01311.x     Document Type: Review

References (108)

1. Cowie CC, Rust KF, Ford ES et al. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006. Diabetes Care 2009; 32: 287-294.
2. Pili-Floury S, Mitifiot F, Penfornis A et al. Glycaemic dysregulation in nondiabetic patients after major lower limb prosthetic surgery. Diabetes Metab 2009; 35: 43-48.
3. Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab 2002; 87: 978-982.
4. Wexler DJ, Nathan DM, Grant RW, Regan S, Van Leuvan AL, Cagliero E. Prevalence of elevated hemoglobin A1c among patients admitted to the hospital without a diagnosis of diabetes. J Clin Endocrinol Metab 2008; 93: 4238-4244.
5. Clement S, Braithwaite SS, Magee MF et al. Management of diabetes and hyperglycemia in hospitals. Diabetes Care 2004; 27: 553-591.
6. Furnary AP, Gao G, Grunkemeier GL et al. Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 2003; 125: 1007-1021.
7. Goldberg PA, Siegel MD, Sherwin RS et al. Implementation of a safe and effective insulin infusion protocol in a medical intensive care unit. Diabetes Care 2004; 27: 461-467.
8. Hermans G, Wilmer A, Meersseman W et al. Impact of intensive insulin therapy on neuromuscular complications and ventilator dependency in the medical intensive care unit. Am J Respir Crit Care Med 2007; 175: 480-489.
9. Lazar HL, Chipkin SR, Fitzgerald CA, Bao Y, Cabral H, Apstein CS. Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events. Circulation 2004; 109: 1497-1502.
10. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 1997; 314: 1512-1515.
11. Malmberg K, Ryden L, Wedel H et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005; 26: 650-661.
12. Scalea TM, Bochicchio GV, Bochicchio KM, Johnson SB, Joshi M, Pyle A. Tight glycemic control in critically injured trauma patients. Ann Surg 2007; 246: 605-610; discussion 10-12.
13. Van den Berghe G, Wilmer A, Milants I et al. Intensive insulin therapy in mixed medical/surgical intensive care units: benefit versus harm. Diabetes 2006; 55: 3151-3159.
14. Van den Berghe G, Wouters P, Weekers F et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345: 1359-1367.
15. Aragon D. Evaluation of nursing work effort and perceptions about blood glucose testing in tight glycemic control. Am J Crit Care 2006; 15: 370-377.
16. Bode BW, Braithwaite SS, Steed RD, Davidson PC. Intravenous insulin infusion therapy: indications, methods, and transition to subcutaneous insulin therapy. Endocr Pract 2004; 10(Suppl. 2): 71-80.
17. Egi M, Bellomo R, Stachowski E et al. Hypoglycemia and outcome in critically ill patients. Mayo Clin Proc 2010; 85: 217-224.
18. Brunkhorst FM, Engel C, Bloos F et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008; 358: 125-139.
19. Wiener RS, Wiener DC, Larson RJ. Benefits and risks of tight glucose control in critically ill adults: a meta-analysis. JAMA 2008; 300: 933-944.
20. Griesdale DE, de Souza RJ, van Dam RM et al. Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. CMAJ 2009; 180: 821-827.
21. Gandhi GY, Murad MH, Flynn DN et al. Effect of perioperative insulin infusion on surgical morbidity and mortality: systematic review and meta-analysis of randomized trials. Mayo Clin Proc 2008; 83: 418-430.
22. Martindale RG, McClave SA, Vanek VW et al. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine and American Society for Parenteral and Enteral Nutrition: executive summary. Crit Care Med 2009; 37: 1757-1761.
23. Rice MJ, Pitkin AD, Coursin DB. Review article: glucose measurement in the operating room: more complicated than it seems. Anesth Analg 2010; 110: 1056-1065.
24. Meier JJ, Weyhe D, Michaely M et al. Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes. Crit Care Med 2004; 32: 848-851.
25. Meijering S, Corstjens AM, Tulleken JE, Meertens JH, Zijlstra JG, Ligtenberg JJ. Towards a feasible algorithm for tight glycaemic control in critically ill patients: a systematic review of the literature. Crit Care 2006; 10: R19.
26. Davies RR, Newton RW, McNeill GP, Fisher BM, Kesson CM, Pearson D. Metabolic control in diabetic subjects following myocardial infarction: difficulties in improving blood glucose levels by intravenous insulin infusion. Scott Med J 1991; 36: 74-76.
27. Hendra TJ, Yudkin JS. An algorithm for tight glycaemic control in diabetic infarct survivors. Diabetes Res Clin Pract 1992; 16: 213-220.
28. Bonnier M, Lonnroth P, Gudbjornsdottir S, Attvall S, Jansson PA. Validation of a glucose-insulin-potassium infusion algorithm in hospitalized diabetic patients. J Intern Med 2003; 253: 189-193.
29. Scott JF, Robinson GM, French JM, O'Connell JE, Alberti KG, Gray CS. Glucose potassium insulin infusions in the treatment of acute stroke patients with mild to moderate hyperglycemia: the Glucose Insulin in Stroke Trial (GIST). Stroke 1999; 30: 793-799.
30. Kanji S, Singh A, Tierney M, Meggison H, McIntyre L, Hebert PC. Standardization of intravenous insulin therapy improves the efficiency and safety of blood glucose control in critically ill adults. Intensive Care Med 2004; 30: 804-810.
31. Barth MM, Oyen LJ, Warfield KT et al. Comparison of a nurse initiated insulin infusion protocol for intensive insulin therapy between adult surgical trauma, medical and coronary care intensive care patients. BMC Emerg Med 2007; 7: 14.
32. Furnary AP, Wu Y. Clinical effects of hyperglycemia in the cardiac surgery population: the Portland Diabetic Project. Endocr Pract 2006; 12(Suppl. 3): 22-26.
33. Studer C, Sankou W, Penfornis A et al. Efficacy and safety of an insulin infusion protocol during and after cardiac surgery. Diabetes Metab 2010; 36: 71-78.
34. Wilson M, Weinreb J, Hoo GW. Intensive insulin therapy in critical care: a review of 12 protocols. Diabetes Care 2007; 30: 1005-1011.
35. Pittas AG, Siegel RD, Lau J. Insulin therapy for critically ill hospitalized patients: a meta-analysis of randomized controlled trials. Arch Intern Med 2004; 164: 2005-2011.
36. Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 2000; 355: 773-778.
37. Kosiborod M, Rathore SS, Inzucchi SE et al. Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes. Circulation 2005; 111: 3078-3086.
38. Krinsley JS. Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients. Mayo Clin Proc 2003; 78: 1471-1478.
39. Whitcomb BW, Pradhan EK, Pittas AG, Roghmann MC, Perencevich EN. Impact of admission hyperglycemia on hospital mortality in various intensive care unit populations. Crit Care Med 2005; 33: 2772-2777.
40. Cheung NW, Wong VW, McLean M. The hyperglycemia: Intensive Insulin Infusion in Infarction (HI-5) study: a randomized controlled trial of insulin infusion therapy for myocardial infarction. Diabetes Care 2006; 29: 765-770.
41. Krinsley JS. Glycemic control, diabetic status, and mortality in a heterogeneous population of critically ill patients before and during the era of intensive glycemic management: six and one-half years experience at a university-affiliated community hospital. Semin Thorac Cardiovasc Surg 2006; 18: 317-325.
42. Rady MY, Johnson DJ, Patel BM, Larson JS, Helmers RA. Influence of individual characteristics on outcome of glycemic control in intensive care unit patients with or without diabetes mellitus. Mayo Clin Proc 2005; 80: 1558-1567.
43. Finfer S, Chittock DR, Su SY et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360: 1283-1297.
44. Krinsley JS. Glycemic variability: a strong independent predictor of mortality in critically ill patients. Crit Care Med 2008; 36: 3008-3013.
45. Egi M, Bellomo R, Stachowski E, French CJ, Hart GK. Variability of blood glucose concentration and short-term mortality in critically ill patients. Anesthesiology 2006; 105: 244-252.
46. Hermanides J, Vriesendorp TM, Bosman RJ, Zandstra DF, Hoekstra JB, Devries JH. Glucose variability is associated with intensive care unit mortality. Crit Care Med 2010; 38: 838-842.
47. Bagshaw RJ, Bellomo R, Jacka MJ et al. The impact of early hypoglycemia and blood glucose variability on outcome in critical illness. Crit Care 2009; 13: R91.
48. Waeschle RM, Moerer O, Hilgers R, Herrmann P, Neumann P, Quintel M. The impact of the severity of sepsis on the risk of hypoglycaemia and glycaemic variability. Crit Care 2008; 12: R129.
49. Ali NA, O'Brien JM Jr, Dungan K et al. Glucose variability and mortality in patients with sepsis. Crit Care Med 2008; 36: 2316-2321.
50. De Jonghe B, Appere-De-Vechi C, Fournier M et al. A prospective survey of nutritional support practices in intensive care unit patients: What is prescribed? What is delivered? Crit Care Med 2001; 29: 8-12.
51. Heyland DK, Schroter-Noppe D, Drover JW et al. Nutrition support in the critical care setting: current practice in Canadian ICUs-opportunities for improvement? JPEN J Parenter Enteral Nutr 2003; 27: 74-83.
52. Hill SA, Nielsen MS, Lennard-Jones JE. Nutritional support in intensive care units in England and Wales: a survey. Eur J Clin Nutr 1995; 49: 371-378.
53. Lipman TO. Grains or veins: Is enteral nutrition really better than parenteral nutrition? A look at the evidence. JPEN J Parenter Enteral Nutr 1998; 22: 167-182.
54. Payne-James JJ, De Gara CJ, Grimble GK et al. Artificial nutrition support in hospitals in the United Kingdom-1991: second national survey. Clin Nutr 1992; 11: 187-192.
55. Preiser JC, Berre J, Carpentier Y et al. Management of nutrition in European intensive care units: results of a questionnaire. Working Group on Metabolism and Nutrition of the European Society of Intensive Care Medicine. Intensive Care Med 1999; 25: 95-101.
56. Gramlich L, Kichian K, Pinilla J, Rodych NJ, Dhaliwal R, Heyland DK. Does enteral nutrition compared to parenteral nutrition result in better outcomes in critically ill adult patients? A systematic review of the literature. Nutrition 2004; 20: 843-848.
57. Dan A, Jacques TC, O'Leary MJ. Enteral nutrition versus glucose-based or lipid-based parenteral nutrition and tight glycaemic control in critically ill patients. Crit Care Resusc 2006; 8: 283-288.
58. Van den Berghe G, Wouters PJ, Bouillon R et al. Outcome benefit of intensive insulin therapy in the critically ill: insulin dose versus glycemic control. Crit Care Med 2003; 31: 359-366.
59. Vriesendorp TM, van Santen S, DeVries JH et al. Predisposing factors for hypoglycemia in the intensive care unit. Crit Care Med 2006; 34: 96-101.
60. Suhaimi F, Le Compte A, Preiser JC et al. What makes tight glycemic control tight? The impact of variability and nutrition in two clinical studies. J Diabetes Sci Technol 2010; 4: 284-298.
61. Marik PE, Preiser JC. Toward understanding tight glycemic control in the ICU: a systematic review and metaanalysis. Chest 2010; 137: 544-551.
62. Losser MR, Damoisel C, Payen D. Glucose metabolism in acute critical situation. Ann Fr Anesth Reanim 2009; 28: e181-e192.
63. Dazzi D, Taddei F, Gavarini A, Uggeri E, Negro R, Pezzarossa A. The control of blood glucose in the critical diabetic patient: a neuro-fuzzy method. J Diabetes Complications 2001; 15: 80-87.
64. Gonzalez-Michaca L, Ahumada M, Ponce-de-Leon S. Insulin subcutaneous application vs. continuous infusion for postoperative blood glucose control in patients with non-insulin-dependent diabetes mellitus. Arch Med Res 2002; 33: 48-52.
65. Jaspers CA, Elte JW, Olthof G. Perioperative diabetes regulation with the help of a standard protocol. Neth J Med 1994; 44: 122-130.
66. Malmberg K, Ryden L, Efendic S et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995; 26: 57-65.
67. Malmberg KA, Efendic S, Ryden LE. Feasibility of insulin-glucose infusion in diabetic patients with acute myocardial infarction. A report from the multicenter trial: DIGAMI. Diabetes Care 1994; 17: 1007-1014.
68. Markovitz LJ, Wiechmann RJ, Harris N et al. Description and evaluation of a glycemic management protocol for patients with diabetes undergoing heart surgery. Endocr Pract 2002; 8: 10-18.
69. Pezzarossa A, Taddei F, Cimicchi MC et al. Perioperative management of diabetic subjects. Subcutaneous versus intravenous insulin administration during glucose-potassium infusion. Diabetes Care 1988; 11: 52-58.
70. Stefanidis A, Melidonis A, Tournis S et al. Intensive insulin treatment reduces transient ischaemic episodes during acute coronary events in diabetic patients. Acta Cardiol 2002; 57: 357-364.
71. Watts NB, Gebhart SS, Clark RV, Phillips LS. Postoperative management of diabetes mellitus: steady-state glucose control with bedside algorithm for insulin adjustment. Diabetes Care 1987; 10: 722-728.
72. Preiser JC, Devos P, Ruiz-Santana S et al. A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study. Intensive Care Med 2009; 35: 1738-1748.
73. Krinsley JS, Grover A. Severe hypoglycemia in critically ill patients: risk factors and outcomes. Crit Care Med 2007; 35: 2262-2267.
74. Kosiborod M, Inzucchi SE, Goyal A et al. Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction. JAMA 2009; 301: 1556-1564.
75. Vlasselaers D, Milants I, Desmet L et al. Intensive insulin therapy for patients in paediatric intensive care: a prospective, randomised controlled study. Lancet 2009; 373: 547-556.
76. Bellomo R, Egi M. Glycemic control in the intensive care unit: why we should wait for NICE-SUGAR. Mayo Clin Proc 2005; 80: 1546-1548.
77. Moghissi ES, Korytkowski MT, DiNardo M et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care 2009; 32: 1119-1131.
78. Dellinger RP, Levy MM, Carlet JM et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36: 296-327.
79. Holst JJ, Vilsboll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 2009; 297: 127-136.
80. Nauck MA. Unraveling the science of incretin biology. Am J Med 2009; 122: S3-S10.
81. Farilla L, Hui H, Bertolotto C et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 2002; 143: 4397-4408.
82. Little TJ, Pilichiewicz AN, Russo A et al. Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. J Clin Endocrinol Metab 2006; 91: 1916-1923.
83. Williams DL, Baskin DG, Schwartz MW. Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. Endocrinology 2009; 150: 1680-1687.
84. Nauck MA, Wollschlager D, Werner J et al. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 1996; 39: 1546-1553.
85. Meneilly GS, McIntosh CH, Pederson RA et al. Effect of glucagon-like peptide 1 on non-insulin-mediated glucose uptake in the elderly patient with diabetes. Diabetes Care 2001; 24: 1951-1956.
86. Nauck MA, Sauerwald A, Ritzel R, Holst JJ, Schmiegel W. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure. Diabetes Care 1998; 21: 1925-1931.
87. Larsen J, Hylleberg B, Ng K, Damsbo P. Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. Diabetes Care 2001; 24: 1416-1421.
88. Zander M, Taskiran M, Toft-Nielsen MB, Madsbad S, Holst JJ. Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes. Diabetes Care 2001; 24: 720-725.
89. Zander M, Christiansen A, Madsbad S, Holst JJ. Additive effects of glucagon-like peptide 1 and pioglitazone in patients with type 2 diabetes. Diabetes Care 2004; 27: 1910-1914.
90. Toft-Nielsen MB, Madsbad S, Holst JJ. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 1999; 22: 1137-1143.
91. Meier JJ, Gallwitz B, Salmen S et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 2719-2725.
92. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36: 741-744.
93. Nauck MA, Weber I, Bach I et al. Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients. Diabet Med 1998; 15: 937-945.
94. Rachman J, Barrow BA, Levy JC, Turner RC. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia 1997; 40: 205-211.
95. Willms B, Idowu K, Holst JJ, Creutzfeldt W, Nauck MA. Overnight GLP-1 normalizes fasting but not daytime plasma glucose levels in NIDDM patients. Exp Clin Endocrinol Diabetes 1998; 106: 103-107.
96. Deane AM, Chapman MJ, Fraser RJ et al. Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: relationship to glycemia. Crit Care Med 2010; 38: 1261-1269.
97. Meneilly GS, Greig N, Tildesley H, Habener JF, Egan JM, Elahi D. Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes. Diabetes Care 2003; 26: 2835-2841.
98. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002; 359: 824-830.
99. Schmoelzer I, Kettler-Schmutt E, Pressl H, Sourij I, Wascher TC. Diabetic Angiopathy Research Group. Efficacy and safety of continuous, intravenous glucagon-like-peptide 1 (GLP-1) in comparison to insulin infusion for normalisation of hyperglycaemia in patients with type 2 diabetes (Abstract). Diabetologia 2007; 50(Suppl. 1): S351.
100. Sokos GG, Bolukoglu H, German J et al. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol 2007; 100: 824-829.
101. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008; 117: 2340-2350.
102. Mussig K, Oncu A, Lindauer P et al. Effects of intravenous glucagon-like peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes. Am J Cardiol 2008; 102: 646-647.
103. Nauck MA, Walberg J, Vethacke A et al. Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1. Regul Pept 2004; 118: 89-97.
104. Deane AM, Chapman MJ, Fraser RJ, Burgstad CM, Besanko LK, Horowitz M. The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study. Crit Care 2009; 13: R67.
105. Yoo BK, Triller DM, Yoo DJ. Exenatide: a new option for the treatment of type 2 diabetes. Ann Pharmacother 2006; 40: 1777-1784.
106. Fehse F, Trautmann M, Holst JJ et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 5991-5997.
107. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 2131-2157.
108. Neumiller JJ. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. J Am Pharm Assoc (2003) 2009; 49(Suppl. 1): S16-S29.